On high-speed rotary presses used for companion-animal oral solids, veterinary-grade pregelatinized hydroxypropyl starch functions concurrently as dry binder and disintegration aid, but the compaction window is narrower than that of unmodified pregelatinized starch because hydroxypropylation reduces the glass transition temperature and increases cold-water swelling. Direct-compression blends for chewable tablets typically incorporate the product at 8–25 % w/w of the core formulation; below 8 % w/w tablet hardness may fall below 40 N on a standard 10.0 mm flat-faced beveled punch, while above 25 % w/w ejection force can exceed 10 kN and sticking on steel tooling becomes more frequent at residual moisture above 10.0 %. Loss-on-drying is controlled according to USP <731> or Ph. Eur. 2.2.32 at 7.0–10.0 %; when the LOD drops below 6.0 %, capping incidence increases on rotary press runs above 80,000 tablets/h. Magnesium stearate blending should not exceed 5 min at 25 rpm in a bin blender because the lubricant coats the starch particles and suppresses water-mediated bonding. Compression is performed with precompression force 3–5 kN and main compression force 8–18 kN, depending on tooling diameter and polymer content; instrumented punch displacement profiles are checked every 15 min during the run to detect changes in precompression energy. Tablet breaking force is measured by USP <1217>, friability by USP <1216>, weight uniformity by USP <905>, disintegration by USP <701> in aqueous media at 37°C with a limit of 15 min, and dissolution by USP <711> apparatus 2 at 50–75 rpm. The finished dosage forms are film-coated tablets, scored chewable tablets for dogs, and mini-tablets for cats. Excipient compliance rests on the current USP-NF Pregelatinized Starch monograph and the Ph. Eur. Pregelatinised starch monograph, with residual solvent testing under USP <467> and VICH GL18 where water is the only processing solvent. In high-humidity manufacturing rooms above 60 % RH, the material should be pre-dried in a fluid-bed dryer at 45–55°C for 30–60 min before weighing, because moisture uptake above 12 % reduces flow and promotes picking during tablet ejection.

Which Wet Granulation Endpoint Parameters Exert the Strongest Influence on Tablet Hardness?

The response of pregelatinized hydroxypropyl starch as a wet-massing binder is governed less by addition level alone than by the water activity at the granulation endpoint and the impeller tip speed during liquid addition. In high-shear mixer granulators with bowl volumes of 25–100 L and impeller tip speeds of 4.0–7.5 m/s, the dry binder is incorporated at 3.0–8.0 % w/w of the dry blend, and purified water is sprayed at 10–25 g/min per kilogram of powder until a target water content of 13–18 % w/w is reached. Granulation endpoint is monitored by impeller power consumption; water addition is stopped when power draw increases by 15–25 % over the dry-mix baseline, and the wet massing is limited to 2–5 min. Extended massing beyond 5 min produces dense, cohesive granules that compress into tablets with disintegration times above 20 min under USP <701>. The wet granules are passed through a 1.6–2.0 mm conical mill, dried in a fluid-bed dryer with inlet air temperature 60–70°C and product temperature 35–42°C to a final LOD of 1.5–3.5 %, then sized through a 0.8–1.2 mm screen. Granule size distribution after dry sizing typically shows a d50 of 150–300 µm and a d90 below 800 µm; overdrying below 1.0 % LOD increases friable fines and promotes capping during compression. Compression on a rotary press proceeds at 15–25 kN main compression force for large veterinary boluses, yielding hardness values of 60–120 N; friability is controlled below 1.0 % according to USP <1216> or Ph. Eur. 2.9.7. Residual water is the only volatile species when aqueous granulation is used, and is confirmed by USP <467> or Ph. Eur. 5.4; nitrosamine risk assessment does not apply to this excipient because no secondary amines are introduced. The terminal product types are oval cattle boluses, swine tablets, and coated oral tablets for small ruminants. Production-scale failure data indicate that when the binder is added above 8.0 % w/w, tablet dissolution declines because the swollen starch forms a viscous gel layer that retards drug release, whereas addition below 3.0 % w/w yields granules with insufficient tensile strength and excessive fines below 20 % of the granule mass.

When a veterinary capsule formulation is transferred from a low-output dosator line to a high-output tamping machine, the dry-binder fraction must compensate for differences in powder column formation and plug ejection. Veterinary-grade pregelatinized hydroxypropyl starch is dry-blended at 15–35 % w/w with milled active pharmaceutical ingredient, a glidant such as colloidal silicon dioxide at 0.5–1.0 % w/w, and a disintegrant if required. The blend is passed through a 0.600 mm sieve and mixed in a bin blender for 15–20 min; powder flow is qualified by USP <1174>, with an angle of repose of 34–40°, bulk density of 0.50–0.65 g/cm³, tapped density of 0.65–0.80 g/cm³, and Carr index 15–25. Encapsulation on a tamping-type machine with 5–8 tamping stations operates at 30,000–90,000 capsules/h; the principal batch-to-batch variance issue is plug weight variation exceeding ±5 % when relative humidity exceeds 65 %, because the pregelatinized particles absorb moisture and become tacky on the dosing disc. Tamping pin pressure is set between 20–60 N depending on fill target, and in-process control samples are pulled every 30 min for weight and appearance. Finished capsules are hard gelatin or HPMC shells, sizes 0–4, intended for oral administration to dogs and cats. Weight uniformity is assessed by USP <905>, dissolution by USP <711> apparatus 1 or 2, and disintegration by USP <701>. Excipient compliance is established through the USP-NF Pregelatinized Starch monograph and the Ph. Eur. Pregelatinised starch monograph; microbial limits are controlled according to USP <61> and USP <62> because oral veterinary capsules are non-sterile dosage forms. In environments where packaging is delayed, the filled capsules should be held in sealed containers with desiccant because moisture uptake above 12 % causes shell softening and cross-linking of gelatin at temperatures above 40°C.

Sedimentation Kinetics and Low-Shear Viscosity in Reconstituted Oral Liquids

In reconstituted oral liquids, veterinary-grade pregelatinized hydroxypropyl starch hydrates in cold water without a cooking step and generates viscosity that slows sedimentation of insoluble drug particles. The additive is dispersed at 0.5–4.0 % w/v in purified water under high-shear mixing at 1,000–3,000 rpm for 15–30 min; for oral solution viscosity modification without suspending solids, the concentration is limited to 0.3–1.5 % w/v because higher levels produce a gel-like mouthfeel that complicates bottle filling. Hydration is completed at 25–40°C, and the pH is adjusted after full swelling to 5.0–7.5 to avoid acid-catalysed hydrolysis of the starch backbone at pH below 4.0. Sedimentation volume measured after 24 h is typically maintained at ≥ 0.90 for suspensions containing micronized active at 1.0–10.0 % w/v; redispersibility after 72 h of quiescent storage requires low-shear viscosity of 150–600 mPa·s at a shear rate of 20 s⁻¹, measured by USP <911> or Ph. Eur. 2.2.8. The terminal product types are veterinary oral suspensions filled into amber polyethylene terephthalate bottles, oral powders for reconstitution in poultry drinking water, and paste-like oral syringes for horses. Compliance for the finished liquid includes preservative effectiveness testing under USP <51> or Ph. Eur. 5.1.3, because pregelatinized starch can support microbial growth if the water activity exceeds 0.85 and the preservative is insufficient. Production-scale observations show that when the polymer is added directly without pre-dispersion, fish-eye agglomerates form and require a secondary high-shear polishing step through a 150 µm screen; this increases batch time by 30–45 min but prevents nozzle clogging during filling. Excipient microbial limits follow USP <61> and USP <62> for non-sterile oral liquids, and residual solvent requirements under USP <467> apply only if solvent-based dispersion aids are used. The vehicle should avoid soluble iron salts and strong oxidising agents, which accelerate oxidative chain scission and reduce viscosity during storage.

For production-animal medicated feed premixes, the primary processing constraint is homogenous dilution of low-dose active pharmaceutical ingredients without segregation or dust formation during transfer and bagging. Veterinary-grade pregelatinized hydroxypropyl starch is employed as a dust-free carrier and diluent at 10–40 % w/w in the premix, depending on the active concentration and the target inclusion rate in final feed. The premix is produced in a ribbon blender with a working capacity of 500–2,000 kg and a mixing time of 15–20 min at 20–30 rpm; particle size of the starch carrier is controlled between 100–250 µm by air-jet milling or sieve classification, giving a bulk density of 0.55–0.68 g/cm³ that matches most mineral carriers and reduces segregation during gravity discharge. The final medicated feed is prepared by dilution at 0.5–5.0 kg/tonne in a horizontal or vertical mixer, with a coefficient of variation below 5 % for active assay. Finished product types are powdered medicated feed premixes, top-dress granules for swine, and mineral-admixture carriers for ruminants. Regulatory compliance for the premix is anchored to EU Regulation 2019/4 for medicated feed manufacture and use, 21 CFR 558 for new animal drugs for use in animal feeds in the United States, and VICH GL18 for residual solvents; microbial quality is assessed by USP <61> and USP <62>. Storage in unlined paper or polyethylene bags above 60 % RH leads to moisture uptake above 9 % and caking in the blender, so bulk silos should be fitted with dehumidified air supply at 40–50 % RH. Unlike direct-compression tablet grades, the feed-premix grade is not required to meet disintegration or dissolution standards, but it must demonstrate batch-to-batch viscosity consistency when the same starch is later reconstituted in drinking-water applications. Transfer lines and bagging heads are operated under negative-pressure dust control to limit operator exposure and prevent cross-contamination between medicated and non-medicated feed batches.

When Terminal Sterilisation Is Replaced by Aseptic Processing in Injectable Suspension Vehicles

Aseptic processing of injectable suspensions containing pregelatinized hydroxypropyl starch requires a different control strategy from oral or feed applications, because the hydrated starch particle cannot pass a sterilising-grade membrane filter and moist-heat terminal sterilisation may alter swelling behaviour and low-shear viscosity. The excipient is incorporated at 0.5–3.0 % w/v as a suspending and viscosity-modifying agent in aqueous injectable suspension vehicles; when the formulation is intended for freeze-dried injection powders, the concentration before lyophilisation is 2.0–5.0 % w/v as a bulking agent or cryoprotectant adjunct, though published data for this specific configuration is limited compared with mannitol and glycine systems. The process sequence begins with dissolution and hydration in a closed jacketed vessel under aseptic conditions at 25–40°C, followed by gentle agitation at 100–300 rpm for 30–60 min to avoid shear-induced viscosity loss. The suspension is transferred to a filling line through 316L stainless steel tubing with no sterilising-grade filter; terminal sterilisation by autoclaving at 121°C for 15 min is used only when the formulation has been validated for post-sterilisation viscosity and sedimentation volume, because retrogradation can produce a denser sediment after heat exposure. For lyophilised products, the freezing step is typically conducted at −45°C and primary drying at −25°C to −15°C under 50–150 µbar, followed by secondary drying at 25°C for 4–6 h; these parameters are adapted from amorphous bulking-agent systems because published data for this specific starch in veterinary freeze-dried injections is limited. Sterility is confirmed by USP <71> or Ph. Eur. 2.6.1; bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14; visible particulate contamination by USP <790> or Ph. Eur. 2.9.20; and uniformity of dosage units by USP <905>. The terminal product types are injectable suspensions for intramuscular or subcutaneous administration to cattle and swine, and freeze-dried powders for injection that are reconstituted with water for injection at the point of use. Excipient-grade material for parenteral use must meet a low-endotoxin specification; the exact limit is derived from the maximum daily dose and target species, and no universal monograph endotoxin limit applies to pregelatinized hydroxypropyl starch. A compliance matrix for the injectable route is provided below.